Alexion moves to dismiss EmblemHealth's US antitrust claims over Soliris
MLex Summary: Alexion Pharmaceuticals moved to dismiss EmblemHealth's US antitrust claims over Soliris, telling a Massachusetts federal judge that Emblem's claims over Alexion's patent litigation against Amgen and Samsung Bioepis challenge...To view the full article, register now.
Already a subscriber? Click here to view full article